BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12

• 

  FDA

  6 FDA Decisions To Watch in Q1 2026

  After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after being delayed from the fourth quarter last year.

  January 12, 2026

   · 

  8 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Biopharma Momentum To Propel Rare Disease, Cancer, Neuro Forward in 2026

  After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told BioSpace, with both rare and chronic diseases headlining investor and R&D interest as JPM26 kicks off.

  January 12, 2026

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Opinion

  To Broaden Access to CAR Ts, Mitigate Their Side Effects

  The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome limits the reach of these transformative cancer therapies.

  January 12, 2026

   · 

  4 min read

   · 

  Teresa Whalen
• 

  Venture capital

  Early-Stage Biotechs Feel the Squeeze as Funding Favors Derisked Assets: JPM

  Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P. Morgan found in a report published ahead of the bank’s annual healthcare conference in San Francisco.

  January 12, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  IPO

  Veradermics, Eikon Eye Public Market Debut as IPO Tap Opens

  Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 million IPO target.

  January 12, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Alzheimer’s disease

  Novartis Makes $1.5B+ Alzheimer’s Play With China’s SciNeuro

  The deal will see Novartis gain global rights over SciNeuro’s potentially disease-modifying anti-amyloid antibody, which leverages the latter’s proprietary shuttle platform to allow delivery into the brain.

  January 12, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Gene editing

  Startup Aurora Seeks To Replicate Baby KJ Success With $16M in Seed Money

  Aurora joins the clutch of companies linked to Nobel Prize winner and CRISPR trailblazer Jennifer Doudna.

  January 12, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Regulatory

  FDA Carves Out Manufacturing Exemptions for CGTs To Accelerate Development

  FDA Commissioner Marty Makary called these changes “common-sense reforms” that could expedite the development of cell and gene therapies.

  January 12, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast

  While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are needed if the biotech hopes to hit its 2028 break-even target.

  January 12, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Policy

  Flagship CEO Calls Out Attacks on Science, Warns of China Dominance

  In his annual letter, Flagship Pioneering’s Noubar Afeyan lays out a choice between near-term “human-made miracles” and a reversion to the pain and suffering of past diseases due to “growing contempt” in the U.S. for the scientific method.

  January 12, 2026

   · 

  4 min read

   · 

  Heather McKenzie